Nektar Therapeutics Stock News

Nektar Therapeutics is down big today after ending some of its clinical trials. What's going on with NKTR stock?

Clinical-stage biotech, Nektar Therapeutics <> has lost more than 53% in the pre-market Monday after the company and Bristol Myers Squibb (BMY) announced a major setback for its…

Nektar Therapeutics (NASDAQ: NKTR ) is trading significantly lower Monday morning after the company''s Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co (NYSE: BMY ), did not meet its primary endpoint. Following a review of the study for efficacy and … Full story available on Benzinga.com

Bristol Myers Squibb (BMY) and Nektar Therapeutics'' (NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line…

Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of bempegaldesleukin combined with Opdivo 

Nektar Therapeutics (NASDAQ: NKTR) is trading significantly lower Monday morning after the company's Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co (NYSE: BMY), did not meet its pr

Cancer drug bempeg was an important one for biotech Nektar and its partner Bristol Myers Squibb.

SAN FRANCISCO, March 14, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022, at 5:00 a.m. Pa

Upgrades Roth Capital upgraded the previous rating for Hudson Technologies Inc (NASDAQ:HDSN) from Neutral to Buy. For the fourth quarter, Hudson Technologies had an EPS of $0.13, compared to year-ago

The trading price of Nektar Therapeutics (NASDAQ:NKTR) closed higher on Tuesday, March 08, closing at $10.34, 2.17% higher than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $9.88 and … Should Value Hunters Buy Nektar Therapeutics (NASDAQ: NKTR) Stock? Read More »

Oppenheimer has upgraded Nektar Therapeutics (NKTR) to outperform from perform given that the stock''s current risk/reward ratio is favorable.

Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.

Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.

Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.